

2014

X-linked agammaglobulinemia presenting as polymicrobial pneumonia, including *Pneumocystis jirovecii*

A. M. Jongco

Zucker School of Medicine at Hofstra/Northwell

J. D. Gough

K. Sarnataro

Northwell Health

D. W. Rosenthal

Zucker School of Medicine at Hofstra/Northwell

J. Moreau

*Northwell Health**See next page for additional authors*Follow this and additional works at: <https://academicworks.medicine.hofstra.edu/articles>Part of the [Pediatrics Commons](#)

Recommended Citation

Jongco A, Gough J, Sarnataro K, Rosenthal D, Moreau J, Ponda P, Bonagura V. X-linked agammaglobulinemia presenting as polymicrobial pneumonia, including *Pneumocystis jirovecii*. . 2014 Jan 01; 112(1):Article 2491 [p.]. Available from: <https://academicworks.medicine.hofstra.edu/articles/2491>. Free full text article.

This Article is brought to you for free and open access by Donald and Barbara Zucker School of Medicine Academic Works. It has been accepted for inclusion in Journal Articles by an authorized administrator of Donald and Barbara Zucker School of Medicine Academic Works. For more information, please contact academicworks@hofstra.edu.

Authors

A. M. Jongco, J. D. Gough, K. Sarnataro, D. W. Rosenthal, J. Moreau, P. Ponda, and V. R. Bonagura



Published in final edited form as:

Ann Allergy Asthma Immunol. 2014 January ; 112(1): . doi:10.1016/j.anai.2013.10.008.

X-linked agammaglobulinemia presenting as polymicrobial pneumonia, including *Pneumocystis jirovecii*

Artemio M. Jongco, MPH, MD, PhD^{a,b}, Jonathan D. Gough, PhD^c, Kyle Sarnataro^a, David W. Rosenthal, DO, PhD^{a,b}, Joanne Moreau, MD^b, Punita Ponda, MD^b, and Vincent R. Bonagura, MD^{a,b}

^aLaboratory of Host Defense, Center for Immunology and Inflammation, Feinstein Institute for Medical Research, Manhasset, New York

^bDivision of Allergy and Immunology, Hofstra North Shore-LIJ School of Medicine, Great Neck, New York

^cDepartment of Chemistry and Biochemistry, Long Island University, Brooklyn, New York

Pneumocystis jirovecii pneumonia is an opportunistic pulmonary infection usually associated with T-cell defects. Clinical and murine studies demonstrate that B-cells and *Pneumocystis*-specific antibodies also contribute to effective immune responses.¹ Patients with primary humoral immunodeficiencies, including X-linked agammaglobulinemia (XLA), may develop *P. jirovecii* pneumonia despite normal T-cell number and function.^{2,3} XLA arises from Bruton tyrosine kinase (BTK) gene mutations, leading to pre-B-cell differentiation arrest, absence of immunoglobulin expression, and increased susceptibility to bacterial/enteroviral infections.⁴ Although more than 600 BTK mutations have been described, new variations/mutations continue to be identified. We describe an infant with a novel BTK kinase domain variation who presented with polymicrobial pneumonia, including *P. jirovecii*.

A 4-month-old former pre-term male infant, born to non-consanguineous parents, without family history of primary or secondary immunodeficiencies, was evaluated for agammaglobulinemia and polymicrobial pneumonia. Newborn screening was unremarkable,

© 2013 American College of Allergy, Asthma and Immunology. Published by Elsevier Inc. All rights reserved.

Corresponding author: Artemio M. Jongco, MPH, MD, PhD, Division of Allergy and Immunology, Hofstra North Shore-LIJ School of Medicine, 865 Northern Blvd., Suite 101, Great Neck, NY 11021, Telephone: 516-622-5070, Fax: 516-622-5060, ajongco@nshs.edu.

Presented in abstract form at the 2013 annual meeting of the Federation of Clinical Immunology Societies, Boston, Massachusetts, June 2013.

The mutant BTK sequence was submitted to GenBank with accession number KF241986.

Author contributions:

Artemio M. Jongco participated in study conception/design, data generation, data analysis/interpretation, and manuscript preparation/revision. Jonathan D. Gough participated in data generation, data analysis/interpretation, and manuscript preparation/revision. Kyle Sarnataro, is currently an undergraduate student who has worked in the laboratory of Dr. Bonagura, has participated in data generation, data analysis/interpretation, and manuscript preparation/revision. David W. Rosenthal participated in study conception/design, data generation, data analysis/interpretation, and manuscript preparation/revision. Joanne Moreau participated in data generation, data analysis/interpretation, and manuscript preparation/revision. Punita Ponda participated in study conception/design, data analysis/interpretation, and manuscript preparation/revision. Vincent R. Bonagura participated in study conception/design, data analysis/interpretation, and manuscript preparation/revision.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

including T-cell receptor excision circle level and HIV-1. He tolerated 2-month vaccinations. He was admitted at age 3.5 months for intermittent increased work of breathing and tachypnea. Chest x-ray (CXR) was normal. He was treated with nebulized albuterol and prednisone. After a short prednisone course, he developed persistent tachypnea and hypoxia, and was admitted to intensive care at age 4 months. On physical examination, lymph node and tonsils were undetectable. Although CXR was normal, chest computed tomography scan showed diffuse ground glass opacities in the right middle lobe. Bronchoscopy was performed and bronchoalveolar lavage (BAL) was positive for *Pneumocystis jirovecii*, *Klebsiella pneumoniae* and *Pseudomonas aeruginosa*. Serum IgG, IgA, IgM, and IgE were undetectable. CBC, C3/C4 levels were normal. Blood and viral cultures were negative. Immunologic evaluation revealed B-cell lymphopenia, elevated CD4⁺CD45RO⁺ and decreased CD4⁺CD45RA⁺ T-cells (Table I).⁵ He responded well to piperacillin/tazobactam, trimethoprim/sulfamethoxazole (TMP-SMX), methylprednisolone, and intravenous immunoglobulin, 0.4 g/kg. He completed 3 weeks of treatment dose TMP-SMX followed by prophylactic dosing. After 1 week, he presented with transient tachypnea. CXR showed bilateral perihilar infiltrates. Silver stain, viral and BAL cultures were negative. He responded to azithromycin and transitioned to subcutaneous immunoglobulin, 0.1 g/kg weekly. He remains well and infection-free with IgG trough levels >500 mg/dL.

BTK genomic sequencing and concurrent targeted array comparative genomic hybridization analysis by GeneDx showed a single adenosine deletion in exon 17 within the kinase domain, causing a frameshift and premature stop codon at residue 569 (c.1701delA (p.Val568SerfsX2)). This variation has not been reported previously in BTKbase version 8.52 or Universal Protein Resource. Two prediction programs, PROVEAN⁶ v1.1.3 and MutationTaster⁶, predicted significantly impaired protein function. MutationTaster⁷ reported another distinct disease-causing mutation at this position. No BTK gene deletion or duplication was identified. BTK expression in peripheral blood mononuclear cells (PBMCs) was evaluated by western blot. Using an anti-amino-terminal antibody recognizing residues 11–26, the control expressed the 76 kiloDalton (kDa) wild type protein, the patient expressed an approximately 66 kDa truncated mutant, while the mother expressed both wild type and truncated proteins, consistent with a BTK carrier. The approximately 60 kDa band detected in all samples likely represents non-specific binding (Supplemental figure 1A). Using an anti-carboxyl-terminal antibody recognizing residues 642–659, the patient had undetectable protein, while the mother expressed diminished wild type protein compared to control (Supplemental figure 1A).

We hypothesized that this expressed truncated protein would be dysfunctional in all BTK-expressing cells. The kinase domain is highly conserved among BTK homologs from diverse organisms, such as zebrafish to primates (data not shown), suggesting that drastic mutations are likely deleterious to proper function. BTK activation begins with transphosphorylation of Y551 in the activation loop (residues 542–559) of the kinase domain by Src-family kinase, followed by autophosphorylation of Y223 in the SH3 domain. X-ray crystal structures of human BTK kinase domain show the importance of Y551 conformation for optimal catalysis and activity.⁸ Molecular dynamics modeling revealed that the truncated protein structurally differs from wild type starting from L547 within the activation loop. Furthermore, Y551 conformationally differs from wild type BTK (Supplemental figure 1B). Thus, the altered structure would impair optimal Y551 transphosphorylation and subsequent Y223 autophosphorylation. Western blot of PBMCs using phosphorylated Y223-specific antibody revealed the patient had undetectable phospho-Y223, whereas his mother expressed reduced levels compared to control (Supplemental figure 1C). These findings suggest that the mutant BTK is inactive.

P. jirovecii pneumonia remains an atypical XLA presentation. Although *Pneumocystis-specific* antibodies are detectable in humans and suspected to be protective based on murine studies, their clinical significance is unclear.¹ Prematurity or corticosteroid use may contribute to increased *P. jirovecii* susceptibility in XLA patients who rarely develop opportunistic infections.⁹ Since BTK is expressed in all hematopoietic cells except T- and plasma cells, BTK deficiency may contribute to antigen presenting cell (APC) dysfunction, leading to impaired innate/adaptive immunity in XLA patients.¹⁰ Recent data suggest that BTK may be a negative regulator of TLR-induced inflammation.¹¹ APC and T-cell function are not universally impaired. XLA patients demonstrate normal APC and T-cell responses to influenza virus¹²⁻¹³ and hepatitis B virus¹⁴ but appear unable to develop lasting T-cell memory responses to meningococcus,¹² suggesting heterogeneity in the ability of XLA patients to respond and maintain T-cell responses to different pathogens. Another possibility is that drastic changes, like kinase domain truncations, may cause more severe phenotypes, but genotype-phenotype correlations are not well established in XLA. Although we did not test APC activation/function in this patient, we suspect that the mutant BTK could cause APC dysfunction. Delayed type hypersensitivity (DTH) to tetanus toxoid at 16 months of age off any corticosteroids, was absent in this patient. Decreased DTH, associated with reduced CD4⁺CD45RO⁺ memory T-cells, has been reported previously in XLA patients,¹⁵ but the underlying mechanism is unclear. This could reflect differences in: 1) local versus circulating APCs; 2) pathogen route of entry/exposure and the efficacy of the ensuing response; 3) severity of the underlying genotype; or 4) altered kinetics of T-cell response in patients versus controls.¹²⁻¹⁵

B-cell lymphopenia may also perturb proper T-cell maturation/function. Reduced memory T-cells have been reported in XLA patients and common variable immunodeficiency (CVID) patients with <2% B-cells,¹⁶ suggesting that B-cell lymphopenia, not BTK deficiency *per se*, may contribute to impaired CD4⁺ T-cell maturation. Murine studies suggest that clearance of *Pneumocystis* depends on B-cell-mediated activation and expansion of effector and memory T-cells.^{1,17} Current data are conflicting on whether B-cells are dispensable in generating effective T-cell memory in humans.¹²⁻¹⁶ Elevated CD4⁺CD45RO⁺ memory T-cells has been reported in CVID patients,¹⁸ but its significance in our patient or his absent DTH is unclear. Further research is needed to investigate these possibilities.

In summary, this patient is a reminder that *P. jirovecii* pneumonia should be considered in XLA patients presenting with respiratory distress. Although BTK is not expressed in T-cells, BTK deficiency may indirectly affect optimal T-cell maturation/activation by modulating APC function. The potential consequences of BTK deficiency in cells other than B-cells should be considered, especially since BTK inhibitors, which irreversibly block BTK activation and function, are being developed for clinical use in malignancy and autoimmune diseases.¹⁹

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We thank Ms. Lynda Hatam and Ms. Fung Lam for assistance with flow cytometry.

Declaration of all sources of funding: Artemio M. Jongco is supported by NIAID T32-AI083223 awarded to Vincent R. Bonagura. Vincent R. Bonagura has received grant support from NIH, CSL-Behring, and is on the speaker's bureau for Baxter. Jonathan D. Gough, Kyle Sarnataro, Joanne Moreau, David W. Rosenthal, and Punita Ponda have no relationships to declare.

References

1. Kelly MN, Shellito JE. Current understanding of *Pneumocystis* immunology. *Future Microbiol.* 2010; 5:43–65. [PubMed: 20020829]
2. Kanegane H, Nakano T, Shimono Y, Zhao M, Miyawaki T. *Pneumocystis jiroveci* pneumonia as an atypical presentation of X-linked agammaglobulinemia. *Int J Hematol.* 2009; 89:716–7. [PubMed: 19399581]
3. Gaspar HB, Ferrando M, Caragol I, et al. Kinase mutant Btk results in atypical X-linked agammaglobulinaemia phenotype. *Clin Exp Immunol.* 2000; 120:346–50. [PubMed: 10792386]
4. Hendriks RW, Bredius RG, Pike-Overzet K, Staal FJ. Biology and novel treatment options for XLA, the most common monogenetic immunodeficiency in man. *Expert Opin Ther Targets.* 2011; 15:1003–21. [PubMed: 21635151]
5. Shearer WT, Rosenblatt HM, Gelman RS, et al. Lymphocyte subsets in healthy children from birth through 18 years of age: the Pediatric AIDS Clinical Trials Group P1009 study. *J Allergy Clin Immunol.* 2003; 112:973–80. [PubMed: 14610491]
6. Choi Y, Sims GE, Murphy S, Miller JR, Chan AP. Predicting the functional effect of amino acid substitutions and indels. *PLoS One.* 2012; 7:e46688. [PubMed: 23056405]
7. Schwarz JM, Rödelsperger C, Schuelke M, Seelow D. MutationTaster evaluates disease-causing potential of sequence alterations. *Nat Methods.* 2010; 7:575–6. [PubMed: 20676075]
8. Marcotte DJ, Liu YT, Arduini RM, et al. Structures of human Bruton's tyrosine kinase in active and inactive conformations suggest a mechanism of activation for TEC family kinases. *Protein Sci.* 2010; 19:429–39. [PubMed: 20052711]
9. Sirianni MC, Atzori C, De Santis W, et al. A case of *Pneumocystis jiroveci* pneumonia in X-linked agammaglobulinaemia treated with immunosuppressive therapy: a lesson for immunologists. *Int Arch Allergy Immunol.* 2006; 140:82–8. [PubMed: 16549936]
10. Taneichi H, Kanegane H, Sira MM, et al. Toll-like receptor signaling is impaired in dendritic cells from patients with X-linked agammaglobulinemia. *Clin Immunol.* 2008; 126:148–54. [PubMed: 18271077]
11. Marron TU, Martinez-Gallo M, Yu JE, Cunningham-Rundles C. Toll-like receptor 4-, 7-, and 8-activated myeloid cells from patients with X-linked agammaglobulinemia produce enhanced inflammatory cytokines. *J Allergy Clin Immunol.* 2012; 129:184–90. e1–4. [PubMed: 22088613]
12. Morales-Aza B, Glennie SJ, Garcez TP, et al. Impaired maintenance of naturally acquired T-cell memory to the meningococcus in patients with B-cell immunodeficiency. *Blood.* 2009; 113:4206–12. [PubMed: 19202131]
13. Liu Y, Wu Y, Lam KT, Lee PP, Tu W, Lau YL. Dendritic and T cell response to influenza is normal in the patients with X-linked agammaglobulinemia. *J Clin Immunol.* 2012; 32:421–9. [PubMed: 22289994]
14. Paroli M, Accapezzato D, Francavilla V, et al. Long-lasting memory-resting and memory-effector CD4+ T cells in human X-linked agammaglobulinemia. *Blood.* 2002; 99:2131–7. [PubMed: 11877289]
15. Crockard AD, Boyd NA, McNeill TA, McCluskey DR. CD4 lymphocyte subset abnormalities associated with impaired delayed cutaneous hypersensitivity reactions in patients with X-linked agammaglobulinaemia. *Clin Exp Immunol.* 1992; 88:29–34. [PubMed: 1373352]
16. Martini H, Enright V, Perro M, et al. Importance of B-cell co-stimulation in CD4(+) T-cell differentiation: X-linked agammaglobulinaemia, a human model. *Clin Exp Immunol.* 2011; 164:381–7. [PubMed: 21488866]
17. Lund FE, Hollifield M, Schuer K, et al. B cells are required for generation of protective effector and memory CD4 cells in response to *Pneumocystis* lung infection. *J Immunol.* 2006; 176:6147–54. [PubMed: 16670323]
18. Vlková M, Thon V, Sárffyová M, et al. Age dependency and mutual relations in T and B lymphocyte abnormalities in common variable immunodeficiency patients. *Clin Exp Immunol.* 2006; 143:373–9. [PubMed: 16412063]

19. Honigberg LA, Smith AM, Sirisawad M, et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. *Proc Natl Acad Sci U S A*. 2010; 107:13075–80. [PubMed: 20615965]

Table I

Summary of clinical laboratory evaluation.

Test	Result	Age-appropriate reference range
CD3 ⁺	3602 (91%)	2500–5600 cells/ μ L (51–77%)
CD4 ⁺	2030 (51%)	1800–4000 cells/ μ L (35–56%)
CD8 ⁺	1461 (37%)	590–1600 cells/ μ L (12–23%)
CD19 ⁺	12 (<1%)	430–3000 cells/ μ L (11–14%)
CD16 ⁺ CD56 ⁺	325 (8%)	170–830 cells/ μ L (3–14%)
CD4 ⁺ 45RA ⁻ 45RO ⁺	24%	3–16% *
CD4 ⁺ 45RA ⁺ 45RO ⁻	58%	77–94% *
CD8 ⁺ 45RA ⁻ 45RO ⁺	2%	1–7% *
CD8 ⁺ 45RA ⁺ 45RO ⁻	95%	85–98% *
Lymphocyte proliferation	PHA: Wnl ConA: Wnl PWM: Wnl	PHA: Wnl ConA: Wnl PWM: Wnl
Natural Killer Cell cytotoxicity	Wnl	Wnl
IgG	Undetectable	251–906 mg/dL
IgA	Undetectable	4–73 mg/dL
IgM	Undetectable	27–101 mg/dL
IgE	Undetectable	0.18–3.76 IU/mL
C3	97	62–175 mg/dL
C4	27	8.3–38 mg/dL
Sweat test	Negative	Negative
Tetanus toxoid DTH	No wheal or flare	Wheal and flare

ConA, concanavalin A; DTH, delayed type hypersensitivity; PHA, phytohemagglutinin; PWM, pokeweed mitogen; Wnl, within normal limits.

* age appropriate reference ranges from reference 5.